Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SAN FRANCISCO, Nov. 03, 2016 -- Hagens Berman Sobol Shapiro LLP alerts investors in Adeptus Health Inc. (NYSE:ADPT) to the securities class action lawsuit filed in the U.S. District Court for the Eastern District of Texas and the Lead Plaintiff deadline of December 27, 2016.
If you acquired securities of Adeptus in its Secondary Public Offering on or about July 31, 2015 or between April 23, 2015 and November 16, 2015 and suffered over $50,000 in losses, contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/ADPT
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On November 17, 2015, an NBC-affiliated television station in Denver, Colorado reported that certain Adeptus Colorado facilities engaged in a pattern and practice of overbilling patients. In response, the price of Adeptus shares fell over 22% to $46.50 on November 17, 2015.
Adeptus failed to disclose their alleged practice of overbilling, instead conducting two secondary public offerings in 2014 and 2015 that reaped over $500 million in net proceeds. Hagens Berman continues to investigate further potential wrongdoing.
“SEC rules are quite clear that issuers must disclose to investors known trends or uncertainties that reasonably could have a material negative impact on the issuer,” said Hagens Berman partner Reed Kathrein. “Adeptus’ predatory conduct, if true, should have been disclosed to investors.”
Whistleblowers: Persons with non-public information regarding Adeptus should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
